Assessing Performance Status in Cancer Patients Using Cardiopulmonary Exercise Testing and Wearable Data Generation: A Prospective Observational Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Malignant Solid Tumor
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Enrollment
- 67
- Locations
- 1
- Primary Endpoint
- Proportion of patients being approached that agree to participate in the study
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The primary objective of this study is to establish the feasibility and value of physical fitness assessment within patients receiving cytotoxic chemotherapy. If successful, this project will establish the groundwork for physical function assessment in larger cancer clinical trials to assist patient selection and evaluation of toxicity and/or response among trial participants.
Detailed Description
Physical fitness, whether measured by performance capacity or daily activity, can predict risk of toxicity while helping to evaluate toxicity itself in the course of cancer chemotherapy. Cytotoxic chemotherapy causes premature aging and frailty in many cancer patients, so measuring and improving physical function may also limit late morbidity and mortality. Clinician-rated performance status (cPS; e.g., ECOG or Karnofsky PS) with or without concomitant organ function testing is the usual gold standard for risk prognostication and patient selection in most cancer settings, but cPS is subjective, unreliable, and relatively sensitive only for patients with significant functional compromise. Objective evaluations of physical function have the potential to augment or even replace cPS in the cancer treatment setting.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients receiving cytotoxic chemotherapy with at least a 3 week cycle (either adjuvant/curative or palliative)
- •Age ≥ 18, prioritizing patients ≥ 60 years
- •At least 6 weeks out from surgical resection
- •Presence of working email address
- •Access to internet at home and either access to wireless internet or cellular data reception
- •Ability to read and understand English
- •Ability to understand and comply with study procedures
Exclusion Criteria
- •Dementia, altered mental status, or psychiatric condition that would prohibit the understanding or rendering of informed consent
- •Contraindication to CPET per standard American Thoracic Society (ATS) guidelines
Outcomes
Primary Outcomes
Proportion of patients being approached that agree to participate in the study
Time Frame: 12 months
Measure 1 for study feasibility
Proportion of patients who wear HealthPatch and have data captured successfully for at least 75% of the time
Time Frame: 12 months
Measure 3 for study feasibility
Patients who wear Philips Actiwatch and have data captured successfully for at least 75% of the time
Time Frame: 12 months
Measure 4 for study feasibility
Proportion of patients who complete both baseline and follow up CPET tests without significant testing-related adverse events
Time Frame: 12 months
Measure 2 for study feasibility
Proportion of patients for whom all data is successfully recorded within the database
Time Frame: 12 months
Measure 5 for study feasibility
Secondary Outcomes
- VO2max measured both pre- and post-chemotherapy(12 months)
- 6 Minute Walk Distance (6MWD)(12 months)
- Clinician-rated performance status(12 months)
- Patient activity/steps per day(12 months)
- Heart rate(12 months)
- Sleep duration(12 months)
- Patient-reported sympotomatic toxicity and quality of life(12 months)
- Incidence and number of falls(12 months)